microbiota activity Microbiota composition
Conditions
Interventions
All subjects will receive amoxicillin (375 mg 3x per day) for 5 days. Group 1
receives a drink with GOS (2,5 g 3x per day) and group 2 receives a drink with
placebo (Maltodextrine 2,5 g 3x per day)
Sponsors
Wageningen Universiteit
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Age: 18-40 • BMI: 18.5-25 kg/m2 • Stable weight over the last 6 months • Western diet • Availability of information about birth by caesarean section and breast-feeding at age 0-3 months • Regular defecation (~1day) • Healthy as judge by the participant himself • Having signed the informed consent form
Exclusion criteria
Exclusion criteria: • Smoking or drug use • Pregnant (include planning to be or gave birth in the last 6 months) or lactating woman • Using contraceptive pill • Gastro-intestinal diseases by the volunteer him/herself or in his/her family (e.g. irritable bowel syndrome, inflammatory bowel disease) • Traveling to an Asian, African or south American country
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is to compare the trends from the in-vivo study to the trends from the parallel in-vitro study regarding the microbiota composition and the microbiota activity. • Microbiota composition : amount of Bifidobacteria, Lactobacillus and Enterobacteriaceae in the faecal samples • Microbiota activity : amount of SCFA and remaining GOS in the faecal samples | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome is to follow up the gastrointestinal symptoms (flatulence, consistency and frequency of faeces, incidence of diarrhoea) of faeces in the in-vivo study. | — |
Countries
Netherlands
Outcome results
None listed